PHARMACOTHERAPEUTIC TRIALS IN ADOLESCENT ALCOHOL USE DISORDERS: OPPORTUNITIES AND CHALLENGES
Identifieur interne : 000964 ( Main/Exploration ); précédent : 000963; suivant : 000965PHARMACOTHERAPEUTIC TRIALS IN ADOLESCENT ALCOHOL USE DISORDERS: OPPORTUNITIES AND CHALLENGES
Auteurs : Michael A. Dawes [États-Unis] ; Bankole A. Johnson [États-Unis]Source :
- Alcohol and Alcoholism [ 0735-0414 ] ; 2004-05.
Abstract
Medications as adjuncts to psychosocial treatments for adolescent alcohol use disorders hold the promise of improved efficacy over psychosocial treatments alone. Specific components should be included in the design and implementation of these medication studies. Included should be assessment of the developmental risks of the chosen medication, consideration of short-term effects on the clinical disorder, factors affecting compliance and retention, age-specific pharmacokinetics, and systematic safety monitoring. A risk–benefit analysis should be conducted on the potential benefits of the medication to decrease alcohol use versus the potential long-term effects of medication use on brain development. To select clinically meaningful subtypes of adolescents with alcohol use disorders for medication trials, classification systems should be derived from multi-factorial models of complex neurodevelopmental disorders. Multi-factorial models will be required to select samples wherein specific gene–gene and gene–environment interactions predict medication treatment response. In samples of adolescents with alcohol use disorders, clinically meaningful subtypes are likely to have differential medication treatment response as a function of age of onset, family history of disorder, and comorbid psychopathology. Findings from preclinical and treatment studies in adults, along with pilot treatment findings in adolescents, suggest that particular serotonergic agents, opioid antagonists, and agents that modulate excitatory amino acids and GABAergic transmission might be effective. Future medication trials for adolescents with alcohol use disorders should use specific combinations of medications, based on specific hypotheses involving key neurotransmitter systems that putatively modulate treatment response. Combinations of medications may have additive effects on particular neurotransmitter systems or synergistic effects across two or more neurotransmitter systems, to further decrease alcohol consumption when compared with single-agent treatment.
Url:
DOI: 10.1093/alcalc/agh045
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001633
- to stream Istex, to step Curation: 001629
- to stream Istex, to step Checkpoint: 000682
- to stream Main, to step Merge: 000969
- to stream Main, to step Curation: 000964
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">PHARMACOTHERAPEUTIC TRIALS IN ADOLESCENT ALCOHOL USE DISORDERS: OPPORTUNITIES AND CHALLENGES</title>
<author><name sortKey="Dawes, Michael A" sort="Dawes, Michael A" uniqKey="Dawes M" first="Michael A." last="Dawes">Michael A. Dawes</name>
</author>
<author><name sortKey="Johnson, Bankole A" sort="Johnson, Bankole A" uniqKey="Johnson B" first="Bankole A." last="Johnson">Bankole A. Johnson</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:A05E06D8CCB4580B1D9CECC7A28365F4BEF1642D</idno>
<date when="2004" year="2004">2004</date>
<idno type="doi">10.1093/alcalc/agh045</idno>
<idno type="url">https://api.istex.fr/document/A05E06D8CCB4580B1D9CECC7A28365F4BEF1642D/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001633</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001633</idno>
<idno type="wicri:Area/Istex/Curation">001629</idno>
<idno type="wicri:Area/Istex/Checkpoint">000682</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000682</idno>
<idno type="wicri:doubleKey">0735-0414:2004:Dawes M:pharmacotherapeutic:trials:in</idno>
<idno type="wicri:Area/Main/Merge">000969</idno>
<idno type="wicri:Area/Main/Curation">000964</idno>
<idno type="wicri:Area/Main/Exploration">000964</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">PHARMACOTHERAPEUTIC TRIALS IN ADOLESCENT ALCOHOL USE DISORDERS: OPPORTUNITIES AND CHALLENGES</title>
<author><name sortKey="Dawes, Michael A" sort="Dawes, Michael A" uniqKey="Dawes M" first="Michael A." last="Dawes">Michael A. Dawes</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Alcohol and Drug Addiction, Department of Psychiatry, The University of Texas Health Science Center at San Antonio, San Antonio, Texas</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Johnson, Bankole A" sort="Johnson, Bankole A" uniqKey="Johnson B" first="Bankole A." last="Johnson">Bankole A. Johnson</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Alcohol and Drug Addiction, Department of Psychiatry, The University of Texas Health Science Center at San Antonio, San Antonio, Texas</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Alcohol and Drug Addiction, Department of Psychiatry, The University of Texas Health Science Center at San Antonio, San Antonio, Texas</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Alcohol and Alcoholism</title>
<title level="j" type="abbrev">Alcohol and Alcoholism</title>
<idno type="ISSN">0735-0414</idno>
<idno type="eISSN">1464-3502</idno>
<imprint><publisher>Oxford University Press</publisher>
<date type="published" when="2004-05">2004-05</date>
<biblScope unit="volume">39</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="166">166</biblScope>
<biblScope unit="page" to="177">177</biblScope>
</imprint>
<idno type="ISSN">0735-0414</idno>
</series>
<idno type="istex">A05E06D8CCB4580B1D9CECC7A28365F4BEF1642D</idno>
<idno type="DOI">10.1093/alcalc/agh045</idno>
<idno type="local">agh045</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0735-0414</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Medications as adjuncts to psychosocial treatments for adolescent alcohol use disorders hold the promise of improved efficacy over psychosocial treatments alone. Specific components should be included in the design and implementation of these medication studies. Included should be assessment of the developmental risks of the chosen medication, consideration of short-term effects on the clinical disorder, factors affecting compliance and retention, age-specific pharmacokinetics, and systematic safety monitoring. A risk–benefit analysis should be conducted on the potential benefits of the medication to decrease alcohol use versus the potential long-term effects of medication use on brain development. To select clinically meaningful subtypes of adolescents with alcohol use disorders for medication trials, classification systems should be derived from multi-factorial models of complex neurodevelopmental disorders. Multi-factorial models will be required to select samples wherein specific gene–gene and gene–environment interactions predict medication treatment response. In samples of adolescents with alcohol use disorders, clinically meaningful subtypes are likely to have differential medication treatment response as a function of age of onset, family history of disorder, and comorbid psychopathology. Findings from preclinical and treatment studies in adults, along with pilot treatment findings in adolescents, suggest that particular serotonergic agents, opioid antagonists, and agents that modulate excitatory amino acids and GABAergic transmission might be effective. Future medication trials for adolescents with alcohol use disorders should use specific combinations of medications, based on specific hypotheses involving key neurotransmitter systems that putatively modulate treatment response. Combinations of medications may have additive effects on particular neurotransmitter systems or synergistic effects across two or more neurotransmitter systems, to further decrease alcohol consumption when compared with single-agent treatment.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Texas</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Texas"><name sortKey="Dawes, Michael A" sort="Dawes, Michael A" uniqKey="Dawes M" first="Michael A." last="Dawes">Michael A. Dawes</name>
</region>
<name sortKey="Johnson, Bankole A" sort="Johnson, Bankole A" uniqKey="Johnson B" first="Bankole A." last="Johnson">Bankole A. Johnson</name>
<name sortKey="Johnson, Bankole A" sort="Johnson, Bankole A" uniqKey="Johnson B" first="Bankole A." last="Johnson">Bankole A. Johnson</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Psychologie/explor/TherFamFrancoV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000964 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000964 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Psychologie |area= TherFamFrancoV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:A05E06D8CCB4580B1D9CECC7A28365F4BEF1642D |texte= PHARMACOTHERAPEUTIC TRIALS IN ADOLESCENT ALCOHOL USE DISORDERS: OPPORTUNITIES AND CHALLENGES }}
This area was generated with Dilib version V0.6.29. |